Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation.

Abstract

Brentuximab vedotin (BV) is a monoclonal antibody-drug conjugate that targets CD30, and has been reported to be effective for relapsed/refractory anaplastic large cell lymphoma. We here report a patient who experienced multiple relapses after conventional chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). He achieved a complete metabolic response with BV and proceeded to undergo haploidentical HSCT. After HSCT, he received three doses of BV to prevent an early relapse, and remains in remission 16 months post-transplantation. Our case suggests the potential use of BV both as a bridging therapy to allogeneic HSCT and as a maintenance therapy post-transplantation.

• Authors: Kyung-Nam Koh, Ho Joon Im, Jin Kyung Suh, Seong Wook Lee, Eun Seok Choi, Jong Jin Seo
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 62 Issue 6 Pg. 1063-5 (Jun 2015) ISSN: 1545-5017 [Electronic] United States
• PMID: 25641881 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2015 Wiley Periodicals, Inc.

Chemical References

• Immunoconjugates
• Brentuximab Vedotin

Topics

• Adolescent
• Brentuximab Vedotin
• Combined Modality Therapy
• Hematopoietic Stem Cell Transplantation
• Humans
• Immunoconjugates (therapeutic use)
• Lymphoma, Large-Cell, Anaplastic (mortality, therapy)
• Male
• Transplantation, Homologous